Skip to main
EVH
EVH logo

Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health (EVH) Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 35%
Buy 52%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Evolent Health Inc. is poised for continued growth, supported by its leadership in specialty-focused value-based care and a track record of exceeding its mid-teens revenue growth target. The company has secured an expected EBITDA improvement of $100 million to $105 million for 2025 through successful Performance Suite negotiations, which will enhance its financial stability and operational efficiency despite some adjustments to product features. Furthermore, the anticipated resilience in Medicaid membership and the expedited timeline to mature margins—projected at 18-24 months—underscore a positive outlook for Evolent Health's financial performance moving forward.

Bears say

Evolent Health Inc. faces significant challenges regarding its membership outlook, as indicated by Humana's revised expectations of a decline of 550,000 in individual MA membership for 2025, which could adversely affect Evolent's own membership associated with Humana. Additionally, the company's client, Florida Blue, is experiencing a membership drop of approximately 35,000, contributing to a broader expectation of reduced revenue prospects through lowered EBITDA estimates for Q4 and into FY25. Furthermore, the company is anticipating headwinds from a declining Medicare membership base, with projections showing a decrease from 250,000 members at year-end 2024 to roughly 217,000 as they enter 2025, which undermines revenue growth potential.

Evolent Health (EVH) has been analyzed by 23 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 52% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolent Health (EVH) Forecast

Analysts have given Evolent Health (EVH) a Buy based on their latest research and market trends.

According to 23 analysts, Evolent Health (EVH) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolent Health (EVH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.